

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**SCHEDULE 14A
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION**

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) (2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to § 240.14a-12

STRATA Skin Sciences, Inc.
(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box)

- No fee required.
- Fee computed on table below per Exchange Act Rules 14a-6(i) (1) and 0-11.
 - (1) Title of each class of securities to which transaction applies:
 - (2) Aggregate number of securities to which transaction applies:
 - (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
 - (4) Proposed maximum aggregate value of transaction:
 - (5) Total fee paid:
- Fee paid previously with preliminary materials.
- Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a) (2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
 - (1) Amount Previously Paid:
 - (2) Form, Schedule or Registration Statement No.:
 - (3) Filing Party:
 - (4) Date Filed:

STRATA Skin Sciences, Inc.
Supplement to the Proxy Statement for the 2017 Annual Meeting of Shareholders
To be held
September 14, 2017



100 Lakeside Drive, Suite 100
Horsham, PA 19044

September 6, 2017

Dear Strata Skin Sciences Stockholder:

The Strata Annual Meeting of Stockholders scheduled for September 14, 2017 is quickly approaching. As your CEO, I am sending this letter to urge you to vote in favor of all of the proposals in the proxy.

For your convenience enclosed is a copy of the proxy statement together with a proxy card that explains how simple and quickly you can register your vote.


In addition to the usual annual stockholder meeting proposals, such as the election of directors, we have a critical proposal on the agenda to which I would like to draw your attention, namely, Proposal Number 2. Proposal No. 2 seeks your approval to implement the agreement that we negotiated with the holders regarding the exchange of over \$40 million in our convertible debentures due in 2021 into equity securities. A full description of the proposal is included in the proxy statement, and I urge you to read it.

Your management team and I want you to bear in mind some critical facts that we believe will help you to decide to vote FOR Proposal No. 2. If our stockholders approve Proposal No. 2, we believe the resulting exchange transaction

- Will eliminate over \$40 million dollars in debt that comes due in 2021 from our balance sheet. Even though you are being asked to authorize the issuance of a significant premium of common stock to make that happen, your management team believes that a vote FOR is in the best interests of the company and its stockholders.
- Will eliminate yearly interest payments of approximately \$1 million to the debenture holders, for a total savings of approximately \$4 million.
- Will enhance our ability to achieve our product development and growth initiatives. Our plans for product development and growth require cash. I and the rest of your team are committed to making this company more successful regardless of the outcome of this vote. However, your vote in favor and the ability to redirect \$1 million in cash into R&D and other projects makes those goals significantly more achievable.
- Will make our stock more attractive to potential investors. Having \$40 million in convertible debentures on the balance sheet appears to be a deterrent to increasing the number and quality of investors in Strata. Removing that debt load should make us more attractive to potential investors.

I urge you to vote in favor of Proposal No. 2 and I would be happy to take any calls or answer any questions you may have regarding this matter. Feel free to call me at (215) 619-3213 or to email me at fmccaney@strataskin.com

Best regards and thank you for your time and consideration,


Frank McCaney
Chief Executive Officer

The Future of Dermatology
strataskin.com

